China Pharma Holdings, Inc.
1.7600+0.01 (+0.34%)
Oct 28, 3:59:09 PM EDT · NYSE American · CPHI · USD
Key Stats
Market Cap
5.74MP/E (TTM)
-Basic EPS (TTM)
-1.48Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
China Pharma's Q2 revenue climbed 11% year-over-year to $1.0M, fueled by gains in anti-viral and cardio products amid market swings, while six-month sales dipped 5.8% to $2.2M. Gross margins sharpened to -8.5% from -109.8% y/y, thanks to lower PP&E amortization and inventory provisions, yet operating losses narrowed to $0.65M from $1.39M. EPS improved to -$0.16, aligning with 3.26M diluted shares post-reverse split. Cash held steady at $0.6M, with $0.23M operating inflow offsetting $0.09M capex for $0.14M free cash flow (derived); lines of credit totaled $2.0M at 3.25-3.6%, backed by CEO guarantees. Losses narrowed, but going concern doubts linger. Customer concentration risks persist.
10-Q
Q1 FY2025 results
China Pharma's Q1 revenue dipped 17% year-over-year to $1.14M, driven by softer sales in anti-viral and respiratory products amid centralized procurement pressures, yet gross loss narrowed to $0.14M from $0.29M as costs fell 23% to $1.27M, lifting the gross margin to -12.0% from -21.2%. Operating loss improved 17% to $0.76M, with expenses steady at $0.62M despite higher intangible amortization; net loss eased to $0.79M or $(0.24) per diluted share on 3.26M shares, versus $(0.72) last year. Cash drained to $0.41M after $0.06M operating outflow, but lines of credit totaling $2.33M at 3.25%-3.9% rates, backed by CEO guarantees and facility collateral, provide breathing room alongside $1.15M related-party borrowings. No M&A or non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles in generic consistency evaluations pose ongoing risks.
8-K
Reverse split details
China Pharma Holdings announced a 1-for-10 reverse stock split, effective April 15, 2025, converting every 10 pre-split shares into one post-split share with no fractional shares issued—instead rounded up. Approved by shareholders on December 22, 2024, and set at this ratio by the board on March 26, 2025, the move aims to adjust share structure while preserving ownership percentages. Trading continues under CPHI on NYSE American. Yet risks like market volatility persist.
10-K
FY2024 results
China Pharma Holdings posted FY2024 revenue of $4.5 million, down 36% y/y from $7.0 million in 2023, as centralized procurement squeezed margins on non-compliant generics like Roxithromycin, while anti-infection/respiratory drugs held 61% of sales but fell 23% y/y. Gross loss widened to $2.0 million (43.8% margin) from $0.3 million (4.0%), driven by $0.66 million in idle equipment costs and $0.86 million inventory impairments amid production cuts. Operating loss hit $4.59 million, up from $2.75 million, with R&D up 17% to $0.28 million on consistency evaluations for Candesartan, which passed in 2023. Cash dipped to $0.63 million, backed by a $1.4 million bank line at 3.25% secured by facilities, yet OEM deals added $53K revenue. Q4 momentum faltered with sequential sales drops, but CMO projects signal diversification. Regulatory hurdles in China's generic market threaten quarterly recovery.
8-K
Annual meeting approves board, plan
China Pharma Holdings held its annual stockholders' meeting on December 22, 2024, with 52% of shares present, electing Zhilin Li and Heung Mei Tsui as non-independent directors for three years and Gene Michael Bennett, Yingwen Zhang, and Baowen Dong as independents for one year. Shareholders approved Amendment No. 2 to the 2010 Long-Term Incentive Plan, a discretionary reverse stock split at a 1:10 to 1:20 ratio, advisory executive compensation, and triennial say-on-pay votes. Directors hold discretion on the split timing. This bolsters governance continuity amid potential share consolidation.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
24.18+0.14
BGM
BGM Group Ltd.
9.38+0.03
COSM
Cosmos Health Inc.
0.94+0.02
CWBHF
Charlotte's Web Holdings Inc.
0.16+0.00
RGC
Regencell Bioscience Holdings L
17.28+0.77
SBFM
Sunshine Biopharma Inc.
1.84-0.12
SXTC
China SXT Pharmaceuticals, Inc.
1.32+0.06
TEVA
Teva Pharmaceutical Industries
19.78+0.17
UPC
Universe Pharmaceuticals Inc
5.13+0.21
VTRS
Viatris Inc.
10.29-0.13